219 related articles for article (PubMed ID: 11042507)
1. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
2. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
3. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
4. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells.
Farahani M; Treweeke AT; Toh CH; Till KJ; Harris RJ; Cawley JC; Zuzel M; Chen H
Leukemia; 2005 Apr; 19(4):524-30. PubMed ID: 15674425
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Schattner EJ; Mascarenhas J; Reyfman I; Koshy M; Woo C; Friedman SM; Crow MK
Blood; 1998 Apr; 91(8):2689-97. PubMed ID: 9531577
[TBL] [Abstract][Full Text] [Related]
6. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia.
Cantwell M; Hua T; Pappas J; Kipps TJ
Nat Med; 1997 Sep; 3(9):984-9. PubMed ID: 9288724
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
Hussein OA; Omran AA; Elnaggar AM; Fathy A
Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
[TBL] [Abstract][Full Text] [Related]
10. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses.
Lee BO; Moyron-Quiroz J; Rangel-Moreno J; Kusser KL; Hartson L; Sprague F; Lund FE; Randall TD
J Immunol; 2003 Dec; 171(11):5707-17. PubMed ID: 14634078
[TBL] [Abstract][Full Text] [Related]
11. Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis.
Lai JH; Luo SF; Ho LJ
Cells; 2019 Aug; 8(8):. PubMed ID: 31426619
[TBL] [Abstract][Full Text] [Related]
12. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS
Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056
[TBL] [Abstract][Full Text] [Related]
14. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
[TBL] [Abstract][Full Text] [Related]
15. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
16. Survival of leukemic B cells promoted by engagement of the antigen receptor.
Bernal A; Pastore RD; Asgary Z; Keller SA; Cesarman E; Liou HC; Schattner EJ
Blood; 2001 Nov; 98(10):3050-7. PubMed ID: 11698290
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Kater AP; Dicker F; Mangiola M; Welsh K; Houghten R; Ostresh J; Nefzi A; Reed JC; Pinilla C; Kipps TJ
Blood; 2005 Sep; 106(5):1742-8. PubMed ID: 15914559
[TBL] [Abstract][Full Text] [Related]
18. CD40 activation: potential for specific immunotherapy in B-CLL.
von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
[TBL] [Abstract][Full Text] [Related]
19. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
[TBL] [Abstract][Full Text] [Related]
20. Does CD40 ligation induce B cell negative selection?
MartÃnez-Barnetche J; Madrid-Marina V; Flavell RA; Moreno J
J Immunol; 2002 Feb; 168(3):1042-9. PubMed ID: 11801637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
